Progressive multifocal leukoencephalopathy (PML), a severe demyelinating disease that is caused by human JC polyomavirus, was first described as a complication of immune suppression 50 years ago and emerged as a major complication of HIV infection in the 1980s. The prognosis has remained dismal since then, with discouraging results from clinical trials of various therapeutic approaches, including immunomodulation and/or inhibition of viral replication. PML is caused by reactivation of latent JC virus, and serotonergic 5-HT2a receptors have been identified as being critical for viral infection of glial cells. In recent years, immunosuppressive therapeutic antibodies have been associated with an increased incidence rate of PML. Here, the authors review findings on the pathogenesis of PML and the encouraging case reports of novel treatments.
Agostini HT, Ryschkewitsch CF, Stoner GL1996. Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. J Clin Microbiol34(1):159-64.
2.
Aksamit A.2006. Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologist12(6):293-8.
3.
Aksamit AJ2001. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J Neurovirol7(4):386-90.
4.
Altschuler EL, Kast RE2005. The atypical antipsychotic agents ziprasidone [correction of zisprasidone], risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. Med Hypotheses65(3):585-6.
5.
Andrei G., Snoeck R., Vandeputte M., De Clercq E.1997. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother41(3):587-93.
6.
Antinori A., Cingolani A., Lorenzini P., Giancola ML, Uccella I., Bossolasco S., and others. 2003. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol9(Suppl 1):47-53.
7.
Astrom KE, Mancall EL, Richardson EP Jr.1958. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain81(1):93-111.
8.
Behzad-Behbahani A., Klapper PE, Vallely PJ, Cleator GM, Khoo SH2004. Detection of BK virus and JC virus DNA in urine samples from immunocompromised (HIV-infected) and immunocompetent (HIV-non-infected) patients using polymerase chain reaction and microplate hybridisation. J Clin Virol29(4):224-9.
9.
Berger J., Koralnik I.2005. Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences. N Engl J Med353:414-6.
10.
Berger J., Pall L., McArthur J.1992. A pilot study of recombinant alpha 2A interferon in the treatment of AIDS-related progressive multifocal leukoencephalopathy [abstract] . Presented at the American Academy of Neurology Annual General Meeting, San Diego, California, May 3-9, 1992.
Bernal-Cano F., Joseph J., Koralnik I.2007. Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. J Neurovirol13(5):474-6.
13.
Blick G., Whiteside M., Griegor P., Hopkins U., Garton T., LaGravinese L.1998. Successful resolution of progressive multifocal leukoencephalopathy after combination therapy with cidofovir and cytosine arabinoside. Clin Infect Dis26(1):191-2.
14.
Boldorini R., Cristina S., Vago L., Tosoni A., Guzzetti S., Costanzi G.1993a. [Anatomo-pathological features of JCV infection in patients with acquired immunodeficiency syndrome (AIDS): histological, immunohistochemical, and ultrastructural study including the in situ hybridization technique of 54 AIDS autopsies]. Pathologica85(1095):17-30. Italian.
15.
Boldorini R., Cristina S., Vago L., Tosoni A., Guzzetti S., Costanzi G.1993b. Ultrastructural studies in the lytic phase of progressive multifocal leukoencephalopathy in AIDS patients. Ultrastruct Pathol17(6):599-609.
16.
Bonig H., Wundes A., Chang KH, Lucas S., Papayannopoulou T.2008a. Increased numbers of circulating hematopoietic stem/ progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood111(7): 3439-41.
17.
Bonig H., Wundes A., Papayannopoulou T.2008b. Response: more about multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors. Blood112(1):209-10.
18.
Brambilla AM, Castagna A., Novati R., Cinque P., Terreni MR, Moioli MC, and others. 1999. Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy. J Neurol246(8):723-5.
19.
Brickelmaier M., Lugovskoy A., Kartikeyan R., Reviriego-Mendoza MM, Allaire N., Simon K., and others. 2009. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother53(5):1840-9.
20.
Britton C., Romagnoli M., Sisti M., Powers JM1992. Progressive multifocal leukoencephalopathy: analysis of outcome and response to intrathecal ara-C in 26 patients [abstract]. In: Program and abstract book: Neuroscience of HIV Infection, Basic and Clinical Frontiers 1992, Amsterdam, July 14-17, 1992:40.
Buckanovich RJ, Liu G., Stricker C., Luger SM, Stadtmauer EA, Schuster SJ, and others. 2002. Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin’s lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy. Ann Hematol81(7):410-3.
23.
Carson K., Bennett C.2009. Rituximab and progressive multifocal leukoencephalopathy: the jury is deliberating. Leuk Lymphoma50(3):323-4.
24.
Carson K., Evens AM, Richey EA, Habermann TM, Focosi D., Seymour JF, and others. 2009. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project. Blood113(20):4834-40.
25.
Cettomai D., McArthur J.2009. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol66(2):255-8.
26.
Chan PA, Wakeman SE, Flanigan T., Cu-Uvin S., Kojic E., Kantor R.2008. HIV-2 diagnosis and quantification in high-risk patients . AIDS Res Ther5:18.
27.
Chang YY, Lan MY, Peng CH, Wu HS, Chang D., Liu JS2007. Progressive multifocal leukoencephalopathy in an immunocompetent Taiwanese patient. J Formos Med Assoc106(2 Suppl):S60-4.
28.
Chapagain M., Sumibcay L., Gurjav U., Kaufusi PH, Kast RE, Nerurkar VR2008. Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells. J Neurovirol14(5):448-54.
29.
Chapagain ML, Verma S., Mercier F., Yanagihara R., Nerurkar VR2007. Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A. Virology364(1):55-63.
30.
Chen Y., Bord E., Tompkins T., Miller J., Tan CS, Kinkel RP, and others. 2009. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med361(11):1067-1074.
31.
Cinque P., Koralnik IJ, Clifford DB2003. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology . J Neurovirol9(Suppl 1):88-92.
32.
Clifford DB, Yiannoutsos C., Glicksman M., Simpson DM, Singer EJ, Piliero PJ, and others. 1999. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology52(3):623-5.
33.
Coleman DV, Wolfendale MR, Daniel RA, Dhanjal NK, Gardner SD, Gibson PE, and others. 1980. A prospective study of human polyomavirus infection in pregnancy. J Infect Dis142(1):1-8.
34.
Colosimo C., Lebon P., Martelli M., Tumminelli F., Mandelli F.1992. Alpha-interferon therapy in a case of probable progressive multifocal leukoencephalopathy. Acta Neurol Belg92(1):24-9.
35.
Conomy JP, Beard NS, Matsumoto H., Roessmann U.1974. Cytarabine treatment of progressive multifocal leukoencephalopathy: clinical course and detection of virus-like particles after antiviral chemotherapy . JAMA229(10):1313-6.
36.
Coppo P., Laporte JP, Aoudjhane M., Lebon P., Isnard F., Lesage S., and others. 1999. Progressive multifocal leucoencephalopathy with peripheral demyelinating neuropathy after autologous bone marrow transplantation for acute myeloblastic leukemia (FAB5). Bone Marrow Transplant23(4):401-3.
37.
De Luca A., Fantoni M., Tartaglione T., Antinori A.1999. Response to cidofovir after failure of antiretroviral therapy alone in AIDS-associated progressive multifocal leukoencephalopathy . Neurology52(4):891-2.
del Pilar Martin M., Cravens PD, Winger R., Frohman EM, Racke MK, Eagar TN, and others.2008. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab . Arch Neurol65(12): 1596-603.
40.
Del Valle L., Gentilella A., Croul S., Khalili K.2000. Detection of HIV-1 Tat and JCV capsid protein, VP1, in AIDS brain with progressive multifocal leukoencephalopathy. J Neurovirol6(3):221-8.
41.
Del Valle L., White MK, Khalili K.2008. Potential mechanisms of the human polyomavirus JC in neural oncogenesis. J Neuropathol Exp Neurol67(8):729-40.
42.
Delbue S., Branchetti E., Bertolacci S., Tavazzi E., Marchioni E., Maserati R., and others. 2009. JC virus VP1 loop-specific polymorphisms are associated with favorable prognosis for progressive multifocal leukoencephalopathy . J Neurovirol15(1):51-6.
43.
Dodge RT1999. A case study: the use of cidofovir for the management of progressive multifocal leukoencephalopathy. J Assoc Nurses AIDS Care10(4):70-4.
44.
Dorries K., Sbiera S., Drews K., Arendt G., Eggers C., Dorries R.2003. Association of human polyomavirus JC with peripheral blood of immunoimpaired and healthy individuals. J Neurovirol9(Suppl 1):81-7.
45.
Du Pasquier RA, Corey S., Margolin DH, Williams K., Pfister LA, De Girolami U., and others. 2003. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology61(6):775-82.
46.
Dugan AS, Gasparovic ML, Atwood WJ2008. Direct correlation between sialic acid binding and infection of cells by two human polyomaviruses (JC virus and BK virus). J Virol82(5):2560-4.
47.
Dutton AC, Massoura AN, Dover TJ, Andrews NA, Barnes NM2008. Identification and functional significance of N-glycosylation of the 5-HT5A receptor. Neurochem Int52(3):419-25.
48.
Egli A., Infanti L., Dumoulin A., Buser A., Samaridis J., Stebler C., and others. Forthcoming 2009 Jan 27. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis.
49.
Elphick GF, Querbes W., Jordan JA, Gee GV, Eash S., Manley K., and others. 2004. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science306(5700):1380-3.
50.
Elsner C., Dorries K.1992. Evidence of human polyomavirus BK and JC infection in normal brain tissue. Virology191(1):72-80.
51.
Fleischmann R.2009. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum60(11):3225-8.
52.
Focosi D.2009. Does contrast enhancement predict survival in progressive multifocal leukoencephalopathy?J Infect Dis199(9):1410-1.
53.
Focosi D., Fazzi R., Montanaro D., Emdin M., Petrini M.2007a. Progressive multifocal leukoencephalopathy in a haploidentical stem cell transplant recipient: a clinical, neuroradiological and virological response after treatment with risperidone. Antiviral Res74(2):156-8.
54.
Focosi D., Kast RE2007. Hyaluronate and risperidone for hemorrhagic cystitis. Bone Marrow Transplant39(1):57.
55.
Focosi D., Kast RE, Maggi F., Ceccherini-Nelli L., Petrini M.2007b. Risperidone-induced reduction in JC viruria as a surrogate marker for efficacy against progressive multifocal leukoencephalopathy and hemorrhagic cystitis. J Clin Virol39(1):63-4.
56.
Focosi D., Kast RE, Maggi F., Ceccherini-Nelli L., Petrini M.2008a. Sialic acid moieties and 5-HT(2a): two faces of the same receptor for JC virus?J Clin Virol43(1):132-3.
57.
Focosi D., Kast RE, Maggi F., Vatteroni L., Ceccherini-Nelli L., Petrini M.2007c. Hypothesis: central nervous system delivery of cyclosporine A for therapy of progressive multifocal leukoencephalopathy. J Clin Virol39(2):156-8.
58.
Focosi D., Kast RE, Maggi F., Ceccherini-Nelli L., Petrini M.2009a. JC virus DNA in healthy brain tissue: a challenge for progressive multifocal leukoencephalopathy diagnosis. Ann Neurol65(2):230.
59.
Focosi D., Kast RE, Petrini M.2008b. JC viremia and multiple sclerosis. J Neurovirol14(1):85-6; author reply 87-8.
60.
Focosi D., Maggi F., Andreoli E., Lanini L., Ceccherini-Nelli L., Petrini M.2009b. Polyomaviruses other than JCV are not detected in progressive multifocal leukoencephalopathy. J Clin Virol45(2):161-2.
61.
Focosi D., Maggi F., Andreoli E., Lanini L., Ceccherini-Nelli L., Petrini M.2009c. The role of bone marrow cells for JCV pathogenicity. J Clin Virol.45(3):230-1.
Gedizlioglu M., Coban P., Ce PS2009. IE, an unusual complication of immunosuppression in myasthenia gravis: progressive multifocal leukoencephalopathy. Neuromuscul Disord19(2):155-7.
64.
Geschwind MD, Skolasky RI, Royal WS, McArthur JC.2001. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol7(4):353-7.
65.
Greenlee J., Clawson SA, Carney HC, O’Neill FJ2005. Detection of JC virus early region sequences of brains of individuals without progressive multifocal leukoencephalopathy. Ann Neurol28(S9):S61.
66.
Hall CD, Dafni U., Simpson D., Clifford D., Wetherill PE, and others. 1998. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med338(19):1345-51.
67.
Happe S., Besselmann M., Matheja P., Rickert CH, Schuierer G., Reichelt D., and others. 1999. [Cidofovir (vistide) in therapy of progressive multifocal leukoencephalopathy in AIDS. Review of the literature and report of 2 cases]. Nervenarzt70(10):935-43. German.
68.
Hartung H.2009. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol8(1):28-31.
69.
Hayashi Y., Kimura A., Kato S., Koumura A., Sakurai T., Tanaka Y., and others. 2008. Progressive multifocal leukoencephalopathy and CD4+ T-lymphocytopenia in a patient with Sjögren syndrome. J Neurol Sci268(1-2):195-8.
70.
Hernandez B., Dronda F., Moreno S.2009. Treatment options for AIDS patients with progressive multifocal leukoencephalopathy. Expert Opin Pharmacother10(3):403-16.
71.
Holman RC, Janssen RS, Buehler JW, Zelasky MT, Hooper WC1998. Progressive multifocal leukoencephalopathy in the United States, 1979-1994: increased mortality associated with HIV infection. Neuroepidemiology17(6):303-9.
72.
Hou J., Major EO1998. The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol4(4):451-6.
73.
Houston S., Roberts N., Mashinter L.2001. Failure of cidofovir therapy in progressive multifocal leukoencephalopathy unrelated to human immunodeficiency virus. Clin Infect Dis32(1):150-2.
74.
Hua-Chuan Z., Lei Y., Lei C., Yi-Fu G., Yasuo T.2009. Mapping the history and current situation of research on John Cunningham virus: a bibliometric analysis. BMC Infect Dis9(1):28.
75.
Huang SS, Skolasky RL, Dal Pan GJ, Royal W, McArthur JC.1998. Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study . J Neurovirol4(3):324-32.
76.
Kamar N., Mengelle C., Rostaing L.2009. Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients. Am J Transplant9(1):244-5.
77.
Kappos L., Bates D., Hartung H.2007. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol6(5):431-41.
78.
Kast RE, Focosi D., Petrini M., Altschuler EL2007. Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone. Bone Marrow Transplant39(12):811-2.
79.
Kato A., Kitamura T., Takasaka T., Tominaga T., Ishikawa A., Zheng HY, and others. 2004. Detection of the archetypal regulatory region of JC virus from the tonsil tissue of patients with tonsillitis and tonsilar hypertrophy. J Neurovirol10(4):244-9.
80.
Khanna N., Elzi L., Mueller NJ, Garzoni C., Cavassini M., Fux CA, and others. 2009. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV cohort study. Clin Infect Dis48(10):1459-66.
81.
Khatri B., Man S., Giovannoni G., Koo AP, Lee J-C., Tucky B., and others. 2009. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology72(5):402-9.
82.
Kiewe P., Seyfert S., Körper S., Rieger K., Thiel E., Knauf W.2003. Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy. Leuk Lymphoma44(10):1815-8.
83.
Kleinschmidt-DeMasters B., Tyler K.2005. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med353(4):369-74.
84.
Kobayashi K., Okamoto Y., Inoue H., Usui T., Ihara M., Kawamata J., an others. 2009. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Intern Med48(15):1307-9.
85.
Koralnik IJ, Boden D., Mai VX, Lord CI, Letvin NL2002. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol168(1):499-504.
86.
Koralnik IJ, Wüthrich C., Dang X., Rottnek M., Gurtman A., Simpson D., and others. 2005. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy . Ann Neurol57(4): 576-80.
87.
Korman B., Tyler K., Korman N.2009. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol145(8): 937-42.
88.
Krumbholz M., Meinl I., Kümpfel T.2008. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology71:1350-4.
89.
Landry ML, Eid T., Bannykh S., Major E.2008. False negative PCR despite high levels of JC virus DNA in spinal fluid: implications for diagnostic testing. J Clin Virol43(2):247-9.
90.
Langer-Gould A., Atlas SW, Green AJ, Bollen AW, Pelletier D.2005. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med353:375-81.
91.
Lanzafame M., Ferrari S., Lattuada E., Corsini F., Deganello R., Vento S., and others. 2009. Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy. Infez Med17(1):35-7.
92.
Lima MA, Auriel E., Wuthrich C., Borenstein NM, Koralnik IJ2005. Progressive multifocal leukoencephalopathy as a complication of hepatitis C virus treatment in an HIV-negative patient. Clin Infect Dis41(3):417-9.
93.
Linda H., von Heijne A., Major EO, Ryschkewitsch C., Berg J., Olsson T., and others. 2009. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med361(11):1081-7.
94.
Liu CK, Wei G., Atwood WJ1998. Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal alpha(2-6)-linked sialic acids. J Virol72(6):4643-9.
95.
Maginnis M., Atwood W.2009. JC virus: an oncogenic virus in animals and humans?Semin Cancer Biol19(4):261-9.
96.
Major E.2010. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med61:35-47.
97.
Malkoun I., Vidry E., Revenco E., Drobacheff MC, Berger E., Rumbach L.2006. [Role of immunity in the development of progressive multifocal leukoencephalopathy: a report of three patients with type B lymphoma and humoral immunodeficiency and six others with acquired immunodeficiency syndrome]. Rev Neurol (Paris) 162(1):82-8. French.
98.
Manley K., O’Hara BA, Gee GV, Simkevich CP, Sedivy JM, Atwood WJ2006. NFAT4 is required for JC virus infection of glial cells . J Virol80(24):12079-85.
99.
Marra CM, Rajicic N., Barker DE, Cohen BA, Clifford D., Donovan Post MJ, and others. 2002. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS16(13):1791-7.
100.
Martin Mdel P., Cravens PD, Winger R., Kieseier BC, Cepok S., Eagar TN, and others. 2009. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol66(8):1016-20.
101.
Martin S., Marty FM, Fiumara K., Treon SP, Gribben JG, Baden LR2006. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis43(1):16-24.
102.
Matoba T., Orba Y., Suzuki T., Makino Y., Shichinohe H., Kuroda S., and others. 2008. An siRNA against JC virus (JCV) agnoprotein inhibits JCV infection in JCV-producing cells inoculated in nude mice. Neuropathology28(3):286-94.
103.
Matteucci P., Magni M., Di Nicola M., Carlo-Stella C., Uberti C., Gianni AM2002. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood100(3):1104-5.
104.
Molloy E., Cabrese L.2008. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev8(2):144-6.
105.
Monaco MC, Atwood WJ, Gravell M., Major EO1996. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol70(10):7004-12.
106.
Monk SA, Williams JM, Hope AG, Barnes NM2004. Identification and importance of N-glycosylation of the human 5-hydroxytryptamine3A receptor subunit. Biochem Pharmacol68(9):1787-96.
107.
Monno L., Di Stefano M., Zimatore GB, Andreula CF, Appice A., Perulli LM, and others. 1998. Measurement of viral sequences in cerebrospinal fluid of AIDS patients with cerebral white-matter lesions using polymerase chain reaction. AIDS12(6): 581-90.
108.
Mori M., Aoki N., Shimada H., Tajima M., Kato K.1992. Detection of JC virus in the brains of aged patients without progressive multifocal leukoencephalopathy by the polymerase chain reaction and Southern hybridization analysis. Neurosci Lett141(2):151-5.
109.
Nived O., Bengtsson AA, Jönsen A., Sturfelt G.2008. Progressive multifocal leukoencephalopathy-the importance of early diagnosis illustrated in four cases. Lupus17(11):1036-41.
110.
Nukuzuma S., Nakamichi K., Nukuzuma C., Takegami T.2009. Inhibitory effect of serotonin antagonists on JC virus propagation in a carrier culture of human neuroblastoma cells. Microbiol Immunol53(9):496-501.
Oshima K., Tsuchiya K., Niizato K., Akiyama H., Arai T., Nagashima K. Forthcoming 2009 Jan 2. Clinicopathological study of early progressive multifocal leukoencephalopathy incidentally found in a schizophrenia patient. Neuropathology.
113.
Owczarczyk K., Hilker R., Brunn A., Hallek M., Rubbert A.2007. Progressive multifocal leucoencephalopathy in a patient with sarcoidosis-successful treatment with cidofovir and mirtazapine. Rheumatology (Oxford) 46(5):888-90.
114.
Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH1971. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet1(7712):1257-60.
115.
Perez-Liz G., Del Valle L., Gentilella A., Croul S., Khalili K.2008. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol64(4):379-87.
116.
Pho MT, Ashok A., Atwood WJ2000. JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J Virol74(5):2288-92.
117.
Pietropaolo V., Videtta M., Fioriti D., Mischitelli M., Arancio A., Orsi N., and others. 2003. Rearrangement patterns of JC virus noncoding control region from different biological samples. J Neurovirol9(6):603-11.
118.
Pineton de Chambrun, G., and others. 2008. Is detection of JC virus DNA in blood a valuable screening test for progressive multifocal leukoencephalopathy in Crohn’s disease patients eligible for anti-α4 integrin therapy?Gut57(11):1633-4.
119.
Polo C., Pérez JL, Mielnichuck A., Fedele CG, Niubò J., Tenorio A.2004. Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children. Clin Microbiol Infect10(7):640-4.
120.
Power C., Gladden JG, Halliday W., Del Bigio MR, Nath A., Ni W., and others. 2000. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology54(3):743-6.
121.
Przepiorka D., Jaeckle KA, Birdwell RR, Fuller GN, Kumar AJ, Huh YO, and others. 1997. Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transplant20(11):983-7. Pugashetti R., Koo J.2009. Efalizumab discontinuation: a practical strategy. J Dermatol Treat20(3):132-6.
122.
Rand KH, Johnson KP, Rubinstein LJ, Wolinsky JS, Penney JB, Walker DL, and others. 1977. Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy: use of virus-containing cells in the urine to assess response to therapy. Ann Neurol1(5):458-62.
123.
Rieckmann P., Michel U., Kehrl JH1994. Regulation of JC virus expression in B lymphocytes. J Virol68(1):217-22.
124.
Rodriguez L., Ribera JM, Batlle M., Xicoy B., Mate J.L., Milla F., and others. 2002. Progressive multifocal leukoencephalopathy shortly after the diagnosis of follicular lymphoma in a patient treated with fludarabine. Haematologica87(7):ECR26.
125.
Royal W. III, Dupont B., McGuire D., Chang L., Goodkin K., Ernst T., and others. 2003. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy . J Neurovirol9(3):411-9.
126.
Salmaggi A., Maccagnano E., Castagna A., Zeni S., Fantini F., Cinque P., and others. 2001. Reversal of CSF positivity for JC virus genome by cidofovir in a patient with systemic lupus erythematosus and progressive multifocal leukoencephalopathy. Neurol Sci22(1):17-20.
127.
Segarra-Newnham M., Vodolo KM2001. Use of cidofovir in progressive multifocal leukoencephalopathy . Ann Pharmacother35(6):741-4.
128.
Sindic C., Trebst C., Van Antwerpen MP, Frye S., Enzensberger W., Hunsmann G., and others. 1997. Detection of CSF-specific oligoclonal antibodies to recombinant JC virus VP1 in patients with progressive multifocal leukoencephalopathy. J Neuroimmunol76(1-2):100-4.
129.
Snyder M., Storch G., Clifford D.2005. Atypical PML leading to a diagnosis of common variable immunodeficiency. Neurology64(9):1661.
Squintani G., Ferrari S., Bazzoli E., Eleopra R., La Monaca C., Cagliari E., and others. Forthcoming 2009 Aug. Progressive multifocal leukoencephalopathy in a patient with Good’s syndrome. Int J Infect Dis.
132.
Steiger MJ, Tarnesby G., Gabe S., McLaughlin J.,. Schapira AH1993. Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. Ann Neurol33(4):407-11.
133.
Study to explore the effect of mefloquinie in subjects with progressive multifocal leukoencephalopathy (PML). 2009. NCT00746941. Available at: www.ClinicalTrials.gov. Accessed February 5, 2009.
134.
Stüve O., Marra CM, Bar-Or A., Niino M., Cravens PD, Cepok S., and others. 2006. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol63(10):1383-7.
135.
Sundsfjord A., and others. 1994. BK and JC viruses in human immunodeficiency virus type 1-infected persons: prevalence, excretion, viremia, and viral regulatory regions. J Infect Dis, 169(3):485-90.
136.
Tada H., Rappaport J., Lashgari M., Amini S., Wong-Staal F., Khalili K.1990. Trans-activation of the JC virus late promoter by the tat protein of type 1 human immunodeficiency virus in glial cells. Proc Natl Acad Sci USA87(9): 3479-83.
137.
Takeda S., Yamazaki K., Miyakawa T., Takahashi H., Ikuta F., Arai H.2009. Progressive multifocal leukoencephalopathy showing extensive spinal cord involvement in a patient with lymphocytopenia. Neuropathology29(4):485-93.
138.
Tallantyre E., Paine SM, Sharp CP, Lowe JS, Gran B.2009. Atypical progressive multifocal leukoencephalopathy associated with an unusual JC polyomavirus mutation. Arch Neurol66(8):1021-4.
139.
Tarsy D., Holden EM, Segarra JM, Calabresi P., Feldman RG1973. 5-Iodo-2′-deoxyuridine (IUDR; NSC-39661) given intraventricularly in the treatment of progressive multifocal leukoencephalopathy. Cancer Chemother Rep57(1):73-8.
140.
Tasca G., Iorio R., Basile U., Lauriola L., Tartaglione R., Mirabella M., and others. 2009. Progressive multifocal leukoencephalopathy in a patient with Franklin disease and hypogammaglobulinemia. J Neurol Sci284(1-2):203-4.
141.
Tuccori M., Focosi D., Blandizzi C., Del Tacca M., Petrini M.2009. Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst101(18):1288-9.
142.
Tyler KL2003. The uninvited guest: JC virus infection of neurons in PML. Neurology61(6):734-5.
143.
US Food and Drug Administration. December 18, 2006. FDA warns of safety concern regarding rituxan in new patient population [FDA News]. Available at: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01532.html. Accessed September 8, 2008.
144.
US Food and Drug Administration.2009. Advisory. Updated safety information about Raptiva (efalizumab). Available at: http://www.fda.gov/cder/drug/advisory/efalizumab.htm
145.
Vago L., Cinque P., Sala E., Nebuloni M., Caldarelli R., Racca S., and others. 1996. JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature. J Acquir Immune Defic Syndr Hum Retrovirol12(2):139-46.
146.
Van Assche G., Van Ranst M., Sciot R., Dubois B., Vermeire S., Noman M., and others. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med353(4):362-8.
147.
Verma S., Cikurel K., Koralnik IJ, Morgello S., Cunningham-Rundles C., Weinstein ZR, and others. 2007. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis196(5):709-11.
Volker H., Kraft K., Arnold E., Steinhoff S., Kolios G., Sommer S.2007. Progressive multifocal leukoencephalopathy developing in advanced pulmonal sarcoidosis. Clin Neurol Neurosurg109(7):624-30.
150.
Vulliemoz S., Lurati-Ruiz S., Borruat F., Delavelle F-X., Koralnik J., Kuntzer IJ, and others. 2006. Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry77(9): 1079-82.
151.
Wang H.2004. Pathologic quiz case: a 54-year-old deceased man with diffuse subcortical lesions of the central nervous system. Progressive multifocal leukoencephalopathy. Arch Pathol Lab Med128(4):e70-2.
152.
Wenning W., Haghikia A., Laubenberger J., Clifford DB, Behrens PF, Chan A., and others. 2009. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med361(11):1075-80.
153.
White FA III, Ishaq M., Stoner GL, Frisque RJ1992. JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J Virol66(10):5726-34.
154.
White MK, Gordon J., Reiss K., Del Valle L., Croul S., Giordano A., and others. 2005. Human polyomaviruses and brain tumors . Brain Res Brain Res Rev50(1):69-85.
155.
Wüthrich C., Dang X., Westmoreland S., McKay J., Maheshwari A., Anderson MP, and others. 2009. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol65(6):742-8.
156.
Wyen C., Hoffmann C., Schmeier N., Wohrmann A., Qurishi N., Rockstroh J., and others. 2004. Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Syndr37(2):1263-8.
157.
Yasuda Y., Yabe H., Inoue H., Shimizu T., Yabe M., Yogo Y., and others. 2003. Comparison of PCR-amplified JC virus control region sequences from multiple brain regions in PML. Neurology61(11):1617-9.
158.
Yousry T., Major EO, Ryschkewitsch C., Fahle G., Fischer S., Hou J., and others. 2006. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med354(9):924-33.
159.
Zheng HY, Ikegaya H., Takasaka T., Matsushima-Ohno T., Sakurai M., Kanazawa I., and others. 2005. Characterization of the VP1 loop mutations widespread among JC polyomavirus isolates associated with progressive multifocal leukoencephalopathy. Biochem Biophys Res Commun333(3): 996-1002.
